Position in LYEL
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$118,594
-$11,697 QoQ
Shares Held
5,912
+39.7% QoQ
Ownership
0.025%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CITIGROUP INC holds $1,427,117,007 across 402 Biotechnology names. LYEL ranks #198 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
682,807 | $304,900,636 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
184,691 | $142,699,654 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
263,375 | $87,142,884 | |
| 4 | MRNA |
Moderna, Inc.
|
1,480,034 | $75,185,727 | |
| 5 | FOLD |
AMICUS THERAPEUTICS, INC.
|
4,226,882 | $61,120,713 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
746,483 | $55,433,827 | |
| 7 | INCY |
Incyte Corp
|
489,649 | $46,085,763 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
1,536,110 | $42,550,246 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $118,594 | 5,912 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $130,291 | 4,233 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $16,727 | 1,030 | Shares | Defined | 2025-11-10 | |
| 2025-06-30 | $18,166 | 2,055 | Shares | Defined | 2025-08-11 | |
| No filing history on record for this holder in this stock. | ||||||